You have read all your free articles, to continue reading subscribe to read the rest of this content.
Researchers at the University of Texas at Austin have a nasal vaccine for the Ebola virus in development that has provided long-term protection for non-human primates against the virus. Small pre-clinical study results are the first to show that a single dose of a non-injectable vaccine for EbolaAlready a subscriber…
Atrogi has received approval from the German authority BfArM to initiate a phase 1 study with their small molecule drug candidate ATR-258 in healthy volunteers and type 2 diabetics. The trial is expected to be completed by year end 2022 with the final report in Q1/2,2023. “Following extensivAlready a subscriber…
AlzeCure Pharma has completed the clinical phase I study (multiple ascending dose, MAD) with repeated dosing of the drug candidate ACD856, with a focus on Alzheimer's disease. Data show that ACD856, the primary drug candidate within the company's NeuroRestore platform, has good tolerability and sAlready a subscriber Login You have…
Xbrane Biopharma has announced results from the six months interim read-out in the Phase III equivalence trial with the Lucentis biosimilar candidate Xlucane. Xlucane met the primary endpoint demonstrating equivalent efficacy in change of BCVA (Best Corrected Visual Acuity) at week 8 of treatmentAlready a subscriber Login You have read…
